|
Jul 31
|
Trump Talks Tough on Drug Prices but His Demands Have Softened
|
|
Jul 31
|
What Trump's Big Pharma CEO letters mean for drug pricing power
|
|
Jul 31
|
Sector Update: Health Care Stocks Fall Late Afternoon
|
|
Jul 31
|
CoreWeave, Arm Holdings, AbbVie: Trending Tickers
|
|
Jul 31
|
Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs
|
|
Jul 31
|
Trump demands largest pharma companies slash US drug prices
|
|
Jul 31
|
Economy Heating Up on PCE for June
|
|
Jul 31
|
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A
|
|
Jul 31
|
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
|
|
Jul 31
|
Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook
|
|
Jul 31
|
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
|
|
Jul 31
|
AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier
|
|
Jul 31
|
PCE Comes in Warmer Than Expected
|
|
Jul 31
|
AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.
|
|
Jul 29
|
AbbVie (ABBV) Files sNDA For Oral VENCLEXTA Combo Regimen In CLL Treatment
|
|
Jul 29
|
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 29
|
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
|
|
Jul 28
|
HS market forecast to reach $7.8bn across 7MM by 2034
|
|
Jul 28
|
Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.
|
|
Jul 28
|
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
|